Get the latest news, insights, and market updates on SLDB (Solid Biosciences Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Solid Biosciences Highlights FDA Path for SGT-003 DMD Study, Shares Early Friedreich’s Ataxia Update
Solid Biosciences (NASDAQ:SLDB) used a presentation at the 2026 Emerging Outlook Biotech Summit to outline its gene therapy-focused pipeline and discuss recent regulatory interactions around its lead Duchenne muscular dystrophy (DMD) program, SGT-003, as well as early progress in Friedreich’s ataxia Feb 15, 2026 - $SLDB
Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy
- IMPACT DUCHENNE: Company aligned with FDA on Phase 3 randomized, double-blind, placebo-controlled trial design -- IMPACT DUCHENNE: Company anticipates first participant dosing in Q1 2026 - - Company plans for additional meetings with the FDA in 1H 2026 to align on a potential accelerated approval pathway for SGT-003 - - INSPIRE DUCHENNE: SGT-003 continues to be generally well tolerated with 36 participants dosed as of February 9, 2026, in Phase 1/2 trial - CHARLESTOWN, Mass., Feb. 09, 2026 (GL Feb 9, 2026 - $SLDB
Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
CHARLESTOWN, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 10:30 AM ET. A live webcast of the presentation will be available on the Events page of the Investors section of the Compan Feb 6, 2026 - $SLDB
Sarepta Stock Climbs. 3-Year Study Results for Elevidys Bring Hope.
Sarepta Therapeutics stock jumped after the company unveiled positive top-line results for a study measuring the efficacy of Elevidys, its controversial blockbuster treatment for Duchenne muscular dystrophy. Patients in the study showed “statistically significant, clinically meaningful and durable efficacy across all key motor function measures” three years after treatment, Sarepta said. The mean North Star Ambulatory Assessment score, a 17-item scale that grades functional motor abilities in patients, remained above baseline for the treated group, while the external control group “continued to show the expected age-related decline below their baseline score,” Sarepta said. Jan 26, 2026 - $SLDB
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101
- Duchenne: Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be generally well tolerated using a steroid-only prophylactic immunomodulation regimen - - Duchenne: First participant enrolled in IMPACT DUCHENNE, a Phase 3 randomized, double-blind, placebo-controlled, ex-U.S. clinical trial, with dosing expected in Q1 2026 - - FA: First participant dosed in Phase 1b FALCON clinical trial; FDA Orphan Drug designation granted to SGT-212 Jan 13, 2026 - $SLDB
Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia
- SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations - - Dosing of the first participant in the Phase 1b FALCON trial has been completed, with initial data expected in H2 2026, subject to participant enrollment - CHARLESTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that U.S. Jan 12, 2026 - $SLDB
Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia
Initial data from the Phase 1b FALCON trial expected in H2 2026, subject to participant enrollmentCHARLESTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the first participant has been dosed in FALCON, the Company’s Phase 1b, first-in-human clinical trial evaluating SGT-212, its investigational gene therapy for Jan 12, 2026 - $SLDB
Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
CHARLESTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 5:15 p.m. PT (8:15 p.m. ET). A live webcast of the presentation will be available on the Events page of the Investors section of Jan 6, 2026 - $SLDB
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple